Loading...
XTAEEMITF-M
Market cap17mUSD
Dec 24, Last price  
591.00ILS
1D
4.81%
1Q
47.79%
Jan 2017
4,401.14%
Name

Elbit Imaging Ltd

Chart & Performance

D1W1MN
XTAE:EMITF-M chart
P/E
—
P/S
19,085.70
EPS
—
Div Yield, %
0.02%
Shrs. gr., 5y
1.18%
Rev. gr., 5y
-30.45%
Revenues
328k
588,623,797816,224,0001,665,605,6503,507,465,6421,098,317,000693,377,0001,473,712,0001,011,298,000671,086,000360,597,000398,578,000347,964,000261,858,000782,829,00000000328,000
Net income
-18m
L+5,733.76%
43,426,88786,884,800559,483,187921,946,379-103,714,000-533,269,00061,998,000-264,919,000-293,590,000-1,155,645,0001,008,999,000-186,150,000-194,830,000-338,034,000-517,833,000-107,497,000229,851,000-20,498,000-311,000-18,143,000
CFO
-3m
L-14.08%
0-99,042,600-521,802,3750220,656,000-754,331,000-334,587,000-240,889,000-148,624,000-16,873,000281,135,000191,353,000158,755,000433,812,000-20,293,000-14,803,000-15,649,000-3,378,000-3,437,000-2,953,000
Dividend
Jun 29, 20230.58332 ILS/sh
Earnings
May 01, 2025

Profile

Elbit Imaging Ltd., together with its subsidiaries, develops, produces, and markets therapeutic medical systems for performing non-invasive treatments on the human body in Israel and internationally. The company offers treatment-oriented medical systems with ultrasound beam and magnetic resonance imaging for noninvasive treatments in human body. It also offers medical products based on stem cells derived primarily from umbilical cord blood and intended for bone marrow transplantation in patients with leukemia or lymph node cancer, non-malignant blood diseases, and metabolic genetic diseases. In addition, the company is involved in the sale of plots and villas in India. The company was formerly known as Elbit Medical Imaging Ltd. and changed its name to Elbit Imaging Ltd. in November 2007. Elbit Imaging Ltd. was incorporated in 1996 and is headquartered in Petach Tikva, Israel.
URL
http://www.elbitimaging.com
IPO date
Nov 01, 1996
Employees
3
Domiciled in
IL
Incorporated in
IL

Valuation

Title
ILS in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
328
 
Cost of revenue
9,669
1,171
1,090
Unusual Expense (Income)
NOPBT
(9,341)
(1,171)
(1,090)
NOPBT Margin
Operating Taxes
52
17
70
Tax Rate
NOPAT
(9,393)
(1,188)
(1,160)
Net income
(18,143)
5,733.76%
(311)
-98.48%
(20,498)
-108.92%
Dividends
(1,333)
(10,071)
(2,500)
Dividend yield
3.47%
2,641.48%
462.54%
Proceeds from repurchase of equity
9,333
(304)
BB yield
-24.28%
56.24%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
618
618
480
Net debt
(39,095)
(33,712)
(45,733)
Cash flow
Cash from operating activities
(2,953)
(3,437)
(3,378)
CAPEX
Cash from investing activities
4,699
23,891
23,581
Cash from financing activities
8,000
(10,071)
(2,804)
FCF
(9,393)
(1,188)
(4,032)
Balance
Cash
41,540
32,075
21,311
Long term investments
(2,445)
1,637
24,422
Excess cash
39,079
33,712
45,733
Stockholders' equity
409,688
249,368
259,750
Invested Capital
24,213
29,569
25,667
ROIC
ROCE
EV
Common stock shares outstanding
9,747
9,143
9,161
Price
3.94
9,355.64%
0.04
-29.32%
0.06
29.67%
Market cap
38,432
9,980.29%
381
-29.46%
540
29.25%
EV
172,844
153,374
143,637
EBITDA
(9,341)
(1,171)
(1,090)
EV/EBITDA
Interest
Interest/NOPBT